A Finnish Diabetes Registry analysis of 45,801 people with type 1 diabetes (2018–2022) found diabetes-related deaths accounted for 12,691 potential years of life lost (PYLL), including 7,654 PYLL from diabetes complications. Average PYLL per diabetes-related death was 20.2 years, with ketoacidosis contributing 4,380 PYLL and severe hypoglycaemia 657 PYLL.

Why It Matters To Your Practice

• PYLL highlights where preventable premature mortality is concentrated: diabetes complications (7,654 PYLL) and ketoacidosis (4,380 PYLL) were major drivers.

• Other large PYLL contributors in this T1D cohort were cardiovascular disease (8,630), cancer (4,549), and alcohol/substance-related causes (3,146).

• Modifiable factors were linked to diabetes-related mortality in multivariable Poisson models, including HbA1c ≥ 64 mmol/mol (≥ 8%), LDL-C ≥ 2.6 mmol/L, renal risk group/ESRD, CVD, and alcohol/substance abuse.

Clinical Benefits

• Sharper risk stratification: use HbA1c, LDL-C, kidney risk/ESRD status, and comorbid CVD to prioritize follow-up intensity and care management.

• Targeted prevention opportunities: reinforce sick-day rules, ketone testing plans, and rapid access pathways to reduce DKA-related harm.

• Earlier complication detection: proactive screening and timely treatment of microvascular complications may reduce the largest diabetes-related PYLL bucket (complications).

Managing Risks

• Address glycemic risk: persistent HbA1c ≥ 8% signals higher mortality risk—consider regimen reassessment, CGM data review, adherence barriers, and referral when needed.

• Mitigate cardiometabolic risk: LDL-C ≥ 2.6 mmol/L and established CVD were associated with diabetes-related mortality—optimize lipid therapy and BP/CVD risk management.

• Protect kidneys: renal risk group and ESRD were linked to diabetes-related mortality—tighten albuminuria/eGFR surveillance and ensure nephrology coordination when indicated.

• Screen for alcohol/substance misuse: association with diabetes-related mortality supports routine screening, brief intervention, and connection to treatment resources.

The Bottom Line

• In Finland, diabetes complications drove 7,654 PYLL in people with T1D—underscoring the clinical payoff of intensified prevention focused on glycemia, lipids/CVD, kidney protection, and substance-use support.